Latest period
$2.99B
YoY change
+3.3%
5Y CAGR
+11.2%
Peak year (2025)
$3.19B
Latest annual
$3.19B
Total Assets history chart for Insulet (PODD) from 2002 to 2025
Latest: $3.19B
Total Assets growth chart for Insulet (PODD) from 2002 to 2025
Latest: +3.3%
Total Assets history table for Insulet (PODD) from 2002 to 2025
| 2025 | $3.19B | +3.3% | +$102.70M | ||
| 2024 | $3.09B | +19.3% | +$499.50M | ||
| 2023 | $2.59B | +15.0% | +$337.10M | ||
| 2022 | $2.25B | +9.9% | +$202.30M | ||
| 2021 | $2.05B | +9.4% | +$175.90M | ||
| 2020 | $1.87B | +63.9% | +$730.00M | ||
| 2019 | $1.14B | +23.1% | +$214.16M | ||
| 2018 | $928.74M | +13.7% | +$112.00M | ||
| 2017 | $816.74M | +78.9% | +$360.10M | ||
| 2016 | $456.65M | +66.0% | +$181.52M | ||
| 2015 | $275.13M | -8.9% | −$27.03M | ||
| 2014 | $302.16M | +4.9% | +$14.20M | ||
| 2013 | $287.95M | +45.4% | +$89.90M | ||
| 2012 | $198.06M | -5.5% | −$11.52M | ||
| 2011 | $209.58M | +34.1% | +$53.35M | ||
| 2010 | $156.23M | -9.0% | −$15.41M | ||
| 2009 | $171.65M | +57.1% | +$62.42M | ||
| 2008 | $109.23M | -16.5% | −$21.51M | ||
| 2007 | $130.74M | +128.8% | +$73.60M | ||
| 2006 | $57.14M | +240.3% | +$40.35M | ||
| 2005 | $16.79M | -38.1% | −$10.33M | ||
| 2004 | $27.12M | +447.0% | +$22.16M | ||
| 2003 | $4.96M | -71.7% | −$12.55M | ||
| 2002 | $17.51M | — | — |
- 2025$3.19B+3.3%
- 2024$3.09B+19.3%
- 2023$2.59B+15.0%
- 2022$2.25B+9.9%
- 2021$2.05B+9.4%
- 2020$1.87B+63.9%
- 2019$1.14B+23.1%
- 2018$928.74M+13.7%
- 2017$816.74M+78.9%
- 2016$456.65M+66.0%
- 2015$275.13M-8.9%
- 2014$302.16M+4.9%
- 2013$287.95M+45.4%
- 2012$198.06M-5.5%
- 2011$209.58M+34.1%
- 2010$156.23M-9.0%
- 2009$171.65M+57.1%
- 2008$109.23M-16.5%
- 2007$130.74M+128.8%
- 2006$57.14M+240.3%
- 2005$16.79M-38.1%
- 2004$27.12M+447.0%
- 2003$4.96M-71.7%
- 2002$17.51M—
Total Assets values are taken from Insulet's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Assets at Insulet (PODD)
According to Insulet's latest reported financial statements, the company's latest reported total assets is $2.99B. Total assets sum everything the company reports owning at the end of each reporting period — cash, receivables, inventory, property, plant, equipment, intangibles, and other holdings — as filed on the balance sheet. Compare with total liabilities and total equity for the capital-structure picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Insulet (PODD) reported total assets of $3.19B – edged up 3.3% year-over-year.
Insulet total assets has grown for 10 consecutive years, with a +11.2% compound annual growth rate over 2020–2025 (5 years).
The highest annual total assets of $3.19B was reported in 2025. The lowest in the available history was $4.96M in 2003.
Insulet Total Assets by Year
Insulet Total Assets 2025: $3.19B
In 2025, Insulet reported total assets of $3.19B, edged up 3.3% from 2024. This figure represents the highest annual value in the available history.
Insulet Total Assets 2024: $3.09B
Insulet total assets in 2024 was $3.09B, grew 19.3% from 2023.
Insulet Total Assets 2023: $2.59B
2023's total assets for Insulet came in at $2.59B, grew 15.0% from 2022.
Insulet Total Assets 2022: $2.25B
Insulet posted total assets of $2.25B in 2022, grew 9.9% from 2021.
Insulet Total Assets 2021: $2.05B
Insulet total assets in 2021 was $2.05B.
See more financial history for Insulet (PODD).
Sector peers by Total Assets
Healthcare peers of Insulet (PODD), ranked by their latest total assets
| $309.58B | |
| $199.21B | |
| $136.87B | |
| $133.96B | |
| $114.07B | |
| $112.48B | |
| $90.59B | |
| $85.37B |
- $309.58B
- $199.21B
- $136.87B
- $133.96B
- $114.07B
- $112.48B
- $90.59B
- $85.37B
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation